Infection in Pulmonary Vascular Disease (iPVD) Consortium
The Infection in Pulmonary Vascular Disease (iPVD) Consortium’s primary focus is to enhance awareness of the role of infection in PVD and to foster research collaborations in infectious diseases across basic science, translational, and clinical aspects, to understand its mechanisms and global impact better. They aim to:
They aim to enhance and support collaborative basic and clinical research on the role of infection in PVDs, by:
- organising epidemiological and field studies on the role of infection in PVDs
- collecting and archiving cases and observations of infection and PVDs
- organising and supporting collaborative research activities on PVDs
They also aim to raise awareness about the role of infection in PVDs, by:
- supporting special sessions on infection and PVD at international conferences on parasitology, immunology, respiratory, cardiology, and specialised PH conferences
- writing a series of research and review articles on the role of infection and PVD in peer-reviewed specialised journals
- organising regular dedicated conferences on the role of infection and PVD
- building an iPVD Consortium website and social media presence to enhance awareness and communication
iPVD Virtual Symposium Webinar Series
These webinars unite international experts to explore the role of infection in PVD. They highlight emerging research across microbiology, immunology, epidemiology, and clinical medicine, creating a global platform for discussion and collaboration.
The Microbes Webinar Series
- Microbes/Parasites and Sex Differences in PVDs, 26 November 2025
- Co-Infection and PVD, November 2024
- Clinical Aspects, August 2024
- Bacteria, May 2024
- Microbiome and microbial metabolites, March 2024
Other webinars
- PH in the Shadow of Infections: Challenges in Indian Practice, August 2025
- Perspectives on global epidemiology challenges, February 2025
iPVD Annual Symposiums
Annual iPVD Consortium meetings are usually held as a pre-conference session at PVRI Conferences. The meetings bring together researchers and clinicians worldwide to share their latest findings on the pathogenesis, diagnosis, and treatment of infectious PVDs. They cover a wide range of topics, including:
- the epidemiology and risk factors for infectious PVDs
- the molecular mechanisms by which infections trigger and worsen PVD
- new diagnostic tools and biomarkers for infectious PVDs
- emerging therapeutic strategies for infectious PVDs
5th iPVD Symposium held at PVRI 2026 Dublin
The programme examined challenges in clinical trials, environmental stressors affecting the pulmonary vasculature, and new insights into the microbiome's role in PVD. Highlights include:
- Highlights of the NIH Sch-PAH multicentre initiative – Brian Graham
- Pathways to diagnose iPVDs in rural areas – Ana Olga Mocumbi
- Extracellular vesicles, exposomes and HIV-associated PH – Navneet Dhillon
- Gut-lung crosstalk in Sch-PH – Suellen D’Arc Oliveira
- Microbiome as a treatment option in PAH – Thenappan Thenappan
Publications
iPVD Consortium members contribute to a growing body of research exploring the links between infection and PVDs. These studies span global epidemiology, disease mechanisms, microbiome research, and infection-driven vascular changes. Recent publications include:
- Oliveira, S.D., Almodóvar, S., Butrous, G., De Jesus Perez, V., Fabro, A. et al. (2024) ‘Infection and pulmonary vascular diseases consortium: United against a global health challenge’. Pulmonary Circulation, 14(4), e70003
- Kumar, R., Aktay-Cetin, Ö., Craddock, V., Morales-Cano, D., Kosanovic, D. et al. (2023) ‘Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities’. PLOS Pathogens, 19(1), e1011063
- Oliveira, R.K.F., Nyasulu, P.S., Iqbal, A.A., Gul, M.H., Ferreira, E.V.M. et al. (2022) ‘Cardiopulmonary disease as sequelae of long-term COVID-19: Current perspectives and challenges’. Frontiers in Medicine, 9, 1041236
- Halawa, S., Pullamsetti, S.S., Bangham, C.R.M., Stenmark, K.R., Dorfmüller, P. et al. (2022) ‘Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: A global perspective’. Nature Reviews Cardiology, 19, 314–331
If you are interested in joining this Task Force, please fill in the form below.
While around 0.5 – 1 million people are affected in high-income countries (HICs), estimates suggest 25–35 million people may be affected in low- and middle- income countries (LMICs). This difference reflects several factors, including:
- higher rates of infectious diseases
- genetic abnormalities
- geographical factors, such as high altitude environmental factors
- differences in healthcare access and medical practice
Understanding these drivers is essential to improving prevention, diagnosis, and care globally.
Our mission is to nurture systematic and coherent efforts to investigate the role and increasing awareness of infection in PVD. We bring together physicians and basic scientists to synergistically fill in the gaps in knowledge while increasing the level of training of junior investigators in the field.
Interested in joining?